Specifically, HMGB1, along with calreticulin, is known to be pivotal for immunogenic cell death (ICD) in CRC treated with oxaliplatin by triggering Toll-like receptor 4 in the immune compartment [112]. The gene discussed is HMGB1; the disease is colorectal carcinoma.